Lung cancer first line treatment has been directed from the non-specific cytotoxic doublet
chemotherapy to the molecular targeted. The major limitation of the targeted therapies still …

In this review, the authors aim to provide an overview of current molecular targeted therapies
for NSCLC, to propose an algorithm for clinical application of presently available treatment …

In recent years, there has been a major paradigm shift in the management of non-small cell
lung cancer (NSCLC). NSCLC should now be further sub-classified by histology and driver …

Non-small cell lung cancer (NSCLC) is one of the most lethal malignancies accountings for
nearly 80% of all lung cancer cases diagnosed and causing over one million deaths …

Despite major advances in the molecular definition of the disease, screening and therapy,
non-small cell lung cancer (NSCLC) is still characterized by a disappointing overall survival …

Lung cancer remains the leading cause of cancer-related mortality in both men and women
in the US and worldwide. Non-small cell lung cancer is the most common variety accounting …

There have been remarkable advances in the targeted treatment of advanced non-small cell
lung cancer (NSCLC) over the past several years. Survival outcomes are steadily improving …

New therapeutic options in non-small-cell lung cancer have been available through a great
in-depth and genomic research, improving preclinical disease patterns and identifying the …

Lung cancer is the leading cause of cancer-related death among men and women in the
United States. Approximately 80-85% of lung cancer cases are non–small-cell lung cancer …

Although tumor molecular-profile-directed therapy appears promising in early clinical
studies, there are many practical challenges to its successful clinical application in non …